<DOC>
	<DOCNO>NCT01994733</DOCNO>
	<brief_summary>Patients end-stage renal disease ( ESRD ) elevate serum phosphate ( P ) level significantly high mortality rate compare normal P. In patient receive conventional dialysis regimen , serum P may lower dietary intervention use P binder , though potentially important side effect may adversely impact quality life . Whether lower P , / target specific P level improve survival clinical outcome unknown . Despite uncertainty , 90 % patient ESRD receive P lower therapy guideline care patient ESRD increasingly call aggressive phosphate lowering . This intensive P lower result extra medication ( associate side-effects ) , high health care cost . We uncertain whether intensification P control result measurable benefit patient ESRD . The overall goal pilot trial evaluate feasibility conduct randomize controlled trial intensive v liberalize phosphate control among hemodialysis recipient .</brief_summary>
	<brief_title>Two phosphAte taRGets End-stage Renal Disease Trial ( TARGET )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Age â‰¥ 18 yr 2 . Receiving chronic hemodialysis &gt; 90 day , 3 . Dialysis prescription currently 4 session per week prescribe 35 hr per session 4 . Most recent P value 1.302.50 mmol/L 5 . Receipt calciumbased P binder 1 . Patient book ( know surgical date ) live donor kidney transplant next 26 week 2 . Planned switch dialysis schedule involve &gt; 16 hour per week therapy within next 26 week . 3 . Planned switch peritoneal dialysis within next 26 week 4 . Pregnancy 5 . Albumincorrected serum calcium &gt; 2.60 mmol/L past year require reduction calcium carbonate dose 6 . History calciphylaxis 7 . Attending nephrologist believe otherwise eligible patient mandate clinical ground P value target &lt; 1.50 mmol/L &gt; 2.00 mmol/L 8 . Attending nephrologist believe otherwise eligible patient candidate escalation current calcium dose 9 . Coenrollment clinical trial intervention deem interfere adherence , safety efficacy intervention provide herein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>end-stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>mineral metabolism</keyword>
	<keyword>serum phosphate</keyword>
	<keyword>phosphate binder</keyword>
</DOC>